Edaravone Dexborneol for Stroke With Active Cancer
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether a combination medicine (edaravone dexborneol) can help people who have both a recent ischemic stroke and an active cancer. The study aims to see if the medication improves recovery without interfering with cancer care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You had a stroke caused by a blood clot (ischemic stroke) within the last 48 hours.
- You have an active cancer (diagnosed in the past year, spread to other parts of the body, or you received treatment for it in the last 30 days).
- You have some weakness in your arm or leg from the stroke, but not so severe that you are completely unable to move them.
- You are able to take study medication and be followed for the duration of the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication (bevifibatide) to see which dose works best for people having an ischemic stroke who cannot get standard treatments like clot-busting drugs or a procedure to remove the clot. It aims to improve recovery by stopping clots from getting worse.
This trial tests whether exosomes from human stem cells can help people recover after a stroke in the front part of the brain. You must start treatment within one week of the stroke, have a certain level of disability, and be generally healthy otherwise.
This trial tests a medicine called edaravone dexborneol for people who have had an acute ischemic stroke (a stroke caused by a blood clot). The goal is to see if it is safe and helps improve recovery when given within 48 hours of the stroke starting.
This trial tests a new sublingual tablet (Edaravone Dexborneol) to help people recover after a small stroke caused by disease of the small blood vessels in the brain. It aims to see if the drug can improve thinking and daily function.
This study tests whether a combination medicine (edaravone dexborneol) can prevent seizures in people who have just had an ischemic stroke (a stroke caused by a blood clot). You would receive this medicine within 48 hours of your stroke if you're at high risk for developing seizures.
This trial studies the safety and effectiveness of edaravone, a neuroprotective drug, in people who have had a mild to moderate stroke in the front part of the brain within the last 48 hours. It aims to see if this drug can help protect the brain from further damage.
Hear when a new Ischemic Stroke, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.